NEWS RELEASE Solasia Announces episil® oral liquid Launched in South Korea Tokyo, Japan, September 23, 2020 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia"), a specialty pharmaceutical company based in Japan, today announced that episil® oral liquid (SP-03, hereinafter "episil®") has been launched in South Korea by its commercialization and promotion partner, Synex Consulting Ltd. (Headquarters: Seoul, South Korea, hereinafter "Synex"). Solasia obtained an exclusive license to develop and commercialize episil® in Japan, China, and...
|
